Standout Papers

Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk 2024 202651
  1. Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk (2024)
    Gerald F. Watts, Robert S. Rosenson et al. New England Journal of Medicine

Immediate Impact

2 from Science/Nature 60 standout
Sub-graph 1 of 22

Citing Papers

Lipoprotein(a) and cardiovascular disease
2024 Standout
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia
2024 Standout
5 intermediate papers

Works of Robert S. Rosenson being referenced

Optimizing Cholesterol Treatment in Patients With Muscle Complaints
2017
Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease
2014
and 2 more

Author Peers

Author Last Decade Papers Cites
Robert S. Rosenson 348 499 330 24 902
Gissette Reyes‐Soffer 352 629 385 37 1.0k
Eliscer Guzman 304 343 244 25 917
Daniel M Hoefner 499 659 300 21 1.0k
Michael J. Blaha 340 498 205 40 844
Anandita Agarwala 347 545 416 58 1.1k
David Colquhoun 334 620 331 16 1.0k
Brian T. Steffen 305 589 376 46 1.1k
Melchior C. Nierman 318 350 519 30 1.0k
Sephy Philip 542 553 353 57 1.0k
Renato Quispe 362 380 228 23 746

All Works

Loading papers...

Rankless by CCL
2026